The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.
Severe congenital hemophilia A (CHA)
Treatment with emicizumab irrespective of any other treatment
Informed consent
No therapy with emicizumab
Immunosuppressive therapy
HIV-infection with CD4 (cluster of differentiation 4) cells <200/µl
Christoph Königs
Lead sponsor
Goethe University
Sponsor institution
Roche Pharma AG
Collaborator
Chugai Pharma Germany GmbH
Collaborator